AF-17 Peptide Disulfide Bridge Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Antisecretory factor (AF) peptide AF-16 has a very short half-life in the body, limiting its effectiveness in treating medical conditions such as diarrhea, inflammation, and traumatic brain injury due to rapid degradation by peptidases.
Innovation Solution
The development of AF-17, a recombinant or synthetically produced peptide with a cysteine disulfide at amino acid position 2, which forms reversibly and protects against peptidase degradation, extending its half-life and allowing it to reach its target intact, thereby optimizing dosage and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AF-16 peptide is administered to treat medical conditions, then antisecretory activity is achieved, but the peptide degrades rapidly by peptidases resulting in very short half-life
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the AF-16 peptide through disulfide bridge formation at specific cysteine positions (C2-C16 or C2-C17). This structural modification changes the peptide's resistance to peptidase degradation, extending its half-life from minutes to hours while preserving its antisecretory biological activity.
Solution Approach 2:
The invention creates a composite structure by forming intramolecular disulfide bonds within the peptide chain, creating a more stable three-dimensional configuration. This composite structural approach protects the peptide backbone from enzymatic cleavage while maintaining the functional conformation necessary for antisecretory action.
2Productivity
If synthetic peptides comprising AF-16 sequence are used, then antisecretory effect is achieved, but rapid peptidase degradation limits effectiveness
Solution Approach 1:
The patent modifies the peptide's chemical parameters by introducing disulfide cross-links at specific positions, changing its susceptibility to peptidase attack. This structural parameter change reduces substance loss through degradation while maintaining the productivity of the antisecretory effect.
Solution Approach 2:
The disulfide bridge formation acts as a preliminary protective measure against peptidase degradation. By pre-establishing these stable covalent bonds, the peptide is protected in advance from enzymatic breakdown, ensuring sustained effectiveness throughout the therapeutic window.
3Reliability
If AF-16 is administered repeatedly to maintain therapeutic effect, then treatment efficacy is improved, but frequent dosing increases treatment complexity
Solution Approach 1:
The patent creates a dynamic balance between peptide stability and biological activity. The disulfide-modified structure provides sufficient stability to maintain therapeutic levels for extended periods, reducing dosing frequency while preserving the dynamic therapeutic effect needed for treating secretory diarrhea and inflammatory conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
AF-17 demonstrates improved stability and effectiveness in normalizing pathological fluid transport and inflammatory reactions, maintaining antisecretory activity, and treating conditions like traumatic brain injury, tumors, and diarrhea, with a prolonged half-life compared to AF-16.
Implementation Method 1
AF-16's major metabolic fate in plasma, which is a rapid disulfide formation of AF16, resulting in AF-16 comprising a cysteine disulfide at amino acid position 2 (C2)
Data Source
AI summary
The present invention relates to a new peptide called Antisecretory Factor (AF) 17 which is an isolated recombinant and/or synthetically produced which has a t½ of at least 1.8 h. The peptide is e.g. useful for normalizing pathological fluid transport and/or inflammatory reactions in animals and in humans. AF-17 and pharmaceutical compositions of AF-17 can e.g. be used for treating and/or preventing TBI and/or secondary brain injuries associated with TBI, as well as for treating and/or preventing acquired brain injuries and to optimize cancer treatment.